4-(1H-benzo [d] imidazole-2-yl)-N, N-bis (2-chloroethyl) aniline derivative and preparation method and application thereof

Synthesis of 4-(1H-benzo[d]imidazol-2-yl)-N,N-bis(2-chloroethyl)aniline derivatives through condensation reaction, solving the low efficacy and toxicity of existing nitrogen mustard drugs. The big problem, achieving simplified synthesis and improving anti-tumor activity, demonstrates the potential value in the treatment of cervical and non-small cell lung cancer.

CN118908896AActive Publication Date: 2024-11-08GUANGDONG OCEAN UNIVERSITY
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
CN202411222549.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-02
Publication Date
2024-11-08
Estimated Expiration
2044-09-02

AI Technical Summary

Technical Problem

Existing nitrogen mustard drugs have problems of low efficacy and great toxicity in tumor treatment, and their synthesis process is complex, making it difficult to optimize drug selectivity and structural modification of carrier parts.

Method used

4-(1H-benzo[d]imidazole-2-yl)-N was synthesized by condensation reaction of 4-position substituted ortho-phenylenediamine with 4-[bis(β-chloroethyl)amino]benzaldehyde. , N-bis(2-chloroethyl)aniline derivatives simplify the synthesis steps and improve the antitumor activity of the drug.

Benefits of technology

This derivative showed significant anti-tumor effect in in vitro experiments, strong ability to inhibit tumor cell proliferation, simple synthesis process, low equipment requirements, and has extensive research and development value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118908896A_ABST
    Figure CN118908896A_ABST
Patent Text Reader

Abstract

The invention discloses a 4-(1H-benzo [d] imidazole-2-yl)-N, N-bis (2-chloroethyl) aniline derivative as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The structural formula of the compound is shown as a formula I: # imgabs0, wherein R substituent is selected from any one of hydrogen, halogen, carboxyl, cyano, nitro and alkoxy. 4-substituted o-phenylenediamine and 4-[bis (beta-chloroethyl) amino] benzaldehyde are used as raw materials, a target molecule is obtained through a condensation reaction, at present, synthesis of similar nitrogen mustard or benzimidazole drugs needs multi-step reactions, and separation and purification are tedious. The synthesis step is only one step, the separation method is simple, and the requirement on equipment is low. In-vitro anti-tumor experiments show that the synthesized target compound has an obvious anti-tumor effect, shows very strong pharmacological activity in the aspect of inhibiting tumor cell proliferation, and has wide research and development values in the field of anti-tumor drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to 4-(1H-benzo[d]imidazol-2-yl)-N,N-bis(2-chloroethyl)aniline derivatives and preparation methods and applications thereof. Background Art

[0002] Nitrogen mustard is one of the earliest drugs used in clinical tumor treatment. Its functional group that exerts its pharmacological action is the alkylation part. For example, the active group of aromatic nitrogen mustard is N, N-bis(2-chloroethyl)aniline. Currently, aromatic nitrogen mustard drugs on the market include chlorambucil. Its mechanism of action is to react with DNA, RNA or enzyme biomacromolecules in cells to produce covalent bonds, causing these biomacromolecules to lose their activity and hindering cell replication, thereby achieving the purpose of anti-tumor. In addition to the alkylation part, the carrier part of nitrogen mustard drugs mainly affects the physicochemical properties of the drug, as well as the pharmacokinetic properties such as absorption and distribution in the body. By selecting different carriers, the purpose of improving drug selectivity and efficacy and reducing toxicity can be achieved. The structural modification of nitrogen mustard compounds is mainly concentrated in the carrier part. Therefore, it is still necessary to develop new nitrogen mustard drugs and obtain the structure-activity relationship between different carriers and activity, so as to provide an important theoretical basis for the development of highly efficient and low-toxic nitrogen mustard anti-tumor drugs. Summary of the invention

[0003] The purpose of the present invention is to provide a 4-(1H-benzo[d]imidazol-2-yl)-N,N-bis(2-chloroethyl)aniline derivative and a preparation method and application thereof, so as to solve the problems existing in the above-mentioned prior art.

[0004] To achieve the above object, the present invention provides the following solutions:

[0005] One of the technical solutions of the present invention is a 4-(1H-benzo[d]imidazol-2-yl)-N,N-bis(2-chloroethyl)aniline derivative, whose structural formula is shown in Formula I:

[0006]

[0007] Wherein, the R substituent is selected from any one of hydrogen, halogen, carboxyl, cyano, nitro and alkoxy.

[0008] The second technical solution of the present invention is a method for preparing the 4-(1H-benzo[d]imidazol-2-yl)-N,N-bis(2-chloroethyl)aniline derivative, comprising the following reactions:

[0009]

[0010] The method comprises the following steps: adding 4-substituted o-phenylenediamine and 4-[bis(β-chloroethyl)amino]benzaldehyde into a solvent, heating for reaction, and then recrystallizing the reaction product to obtain the 4-(1H-benzo[d]imidazol-2-yl)-N,N-bis(2-chloroethyl)aniline derivative.

[0011] The third technical solution of the present invention is the use of the 4-(1H-benzo[d]imidazol-2-yl)-N,N-bis(2-chloroethyl)aniline derivative in the preparation of anti-tumor drugs, wherein the tumor is cervical cancer or non-small cell lung cancer.

[0012] The fourth technical solution of the present invention is an anti-tumor drug, comprising the 4-(1H-benzo[d]imidazol-2-yl)-N,N-bis(2-chloroethyl)aniline derivative.

[0013] Based on the above technical solution, the present invention has the following technical effects:

[0014] The present invention uses 4-substituted o-phenylenediamine and 4-[bis(β-chloroethyl)amino]benzaldehyde as raw materials to obtain the target molecule through condensation reaction. Currently, the synthesis of similar nitrogen mustard or benzimidazole drugs requires multiple steps of reaction, and separation and purification are cumbersome. The present invention only requires one step of synthesis, the separation method is simple, and the equipment requirements are low. In vitro anti-tumor experiments show that the target compounds synthesized by the present invention have obvious anti-tumor effects, show strong pharmacological activity in inhibiting tumor cell proliferation, and have extensive research and development value in the field of anti-tumor drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0016] Figure 1 This is a graph showing the experimental results of the anti-proliferation activity of the product 1a prepared in Example 1 of the present invention on A549 cells and Hela cells.

[0017] Figure 2 This is a graph showing the experimental results of the anti-proliferation activity of product 1b prepared in Example 2 of the present invention on A549 cells and Hela cells.

[0018] Figure 3 This is a graph showing the experimental results of the anti-proliferation activity of product 1c prepared in Example 3 of the present invention on A549 cells and Hela cells.

[0019] Figure 4This is a graph showing the experimental results of the anti-proliferation activity of product 1d prepared in Example 4 of the present invention on A549 cells and Hela cells.

[0020] Figure 5 This is a graph showing the experimental results of the anti-proliferation activity of the product 1e prepared in Example 5 of the present invention on A549 cells and Hela cells.

[0021] Figure 6 This is a graph showing the experimental results of the anti-proliferation activity of product 1f prepared in Example 6 of the present invention on A549 cells and Hela cells.

[0022] Figure 7 This is a graph showing the experimental results of the anti-proliferative activity of 1g of the product prepared in Example 7 of the present invention on A549 cells and Hela cells.

[0023] Figure 8 This is a graph showing the anti-proliferation activity experimental results of the product prepared in Example 8 of the present invention on A549 cells and Hela cells for 1 hour. DETAILED DESCRIPTION

[0024] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0025] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0026] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0027] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present application description and examples are exemplary only.

[0028] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0029] The technical solutions described in the present invention, unless otherwise specified, are all conventional solutions in the art, and the reagents or raw materials used, unless otherwise specified, are purchased from commercial channels or have been disclosed.

[0030] The embodiment of the present invention provides a 4-(1H-benzo[d]imidazol-2-yl)-N,N-bis(2-chloroethyl)aniline derivative, the structural formula of which is shown in Formula I:

[0031]

[0032] Wherein, the R substituent is selected from any one of hydrogen, halogen, carboxyl, cyano, nitro and alkoxy.

[0033] In some specific embodiments, the 4-(1H-benzo[d]imidazol-2-yl)-N,N-bis(2-chloroethyl)aniline derivative is:

[0034]

[0035] The present invention also provides a method for preparing the 4-(1H-benzo[d]imidazol-2-yl)-N,N-bis(2-chloroethyl)aniline derivative, comprising the following reaction:

[0036]

[0037] The method comprises the following steps: adding 4-substituted o-phenylenediamine and 4-[bis(β-chloroethyl)amino]benzaldehyde into a solvent, heating for reaction, and then recrystallizing the reaction product to obtain the 4-(1H-benzo[d]imidazol-2-yl)-N,N-bis(2-chloroethyl)aniline derivative.

[0038] In some specific embodiments, the molar ratio of the 4-substituted o-phenylenediamine to 4-[bis(β-chloroethyl)amino]benzaldehyde is 1:1.

[0039] In some specific embodiments, the solvent is selected from at least one of ethanol, propanol, N,N-dimethylformamide (DMF) and N,N-dimethylacetamide.

[0040] In some specific embodiments, the conditions of the heating reaction are: the reaction is carried out under the catalysis of a catalyst, the reaction temperature is 110° C. to 150° C., and the reaction time is 4 to 10 hours.

[0041] In some specific embodiments, the catalyst is selected from at least one of acetic acid, propionic acid and p-toluenesulfonic acid.

[0042] In some specific embodiments, the recrystallization solvent is: dichloromethane:methanol=1:3 (V / V).

[0043] The embodiment of the present invention also provides the use of the 4-(1H-benzo[d]imidazol-2-yl)-N,N-bis(2-chloroethyl)aniline derivative in the preparation of anti-tumor drugs, wherein the tumor is cervical cancer or non-small cell lung cancer.

[0044] The embodiment of the present invention further provides an anti-tumor drug, comprising the 4-(1H-benzo[d]imidazol-2-yl)-N,N-bis(2-chloroethyl)aniline derivative.

[0045] In some specific embodiments, a pharmaceutically acceptable excipient is also included.

[0046] Benzimidazole compounds have unique chemical structures, produce unique biological activities and pharmacological effects, and play an important role in anti-tumor, anti-viral and anti-bacterial effects. The introduction of different functional groups or substituents on the imidazole ring can regulate its physicochemical properties and physiological activities. The present invention combines two functional groups, 4-substituted benzimidazole and N, N-bis (2-chloroethyl) aniline, to synthesize a 4- (1H-benzo [d] imidazole-2-yl) -N, N-bis (2-chloroethyl) aniline derivative.

[0047] The present invention synthesizes new derivatives by combining benzimidazole and nitrogen mustard functional groups. The synthesis method is simple and easy, and the separation is simple. The prepared target molecules have good anti-tumor activity and show strong pharmacological activity in inhibiting tumor cell proliferation.

[0048] Example 1

[0049] The structural formula of compound 1a is as follows:

[0050]

[0051] Preparation of compound 1a:

[0052] o-phenylenediamine (1 mmol) and 4-[bis(β-chloroethyl)amino]benzaldehyde (1 mmol) were added to DMF (20 mL), and propionic acid (20 μL) was added and heated at 120°C for 8 hours. Then the solvent was removed, washed with water, freeze-dried, and the crude product was recrystallized from dichloromethane:methanol=1:3 (V / V) to obtain compound 1a.

[0053] Characterization data: 1 H NMR (600 MHz, DMSO-d6 )δ:12.66(s,1H,NH),8.01(d,2H,J=9.01Hz,ArH),7.54-7.49(m,2H,ArH);7.16-7.12(m,2H,ArH);6.91(d,2H,J=9.01Hz,ArH),3.85-3.77(m,8H,CH 2 ). 13 C NMR (150 MHz, DMSO-d 6 )δ:151.81,147.73,127.97,121.53,118.23,111.82,51.88,41.09.HR-MS(ESI)calcd for C 17 H 18 Cl 2 N 3 [M+H] + 334.0878, found 334.0881.

[0054] Example 2

[0055] The structural formula of compound 1b is as follows:

[0056]

[0057] Preparation of compound 1b:

[0058] 4-Methoxy-o-phenylenediamine (1 mmol) and 4-[bis(β-chloroethyl)amino]benzaldehyde (1 mmol) were added to DMF (20 mL), propionic acid (20 μL) was added, and the mixture was heated at 120°C for 8 hours. Then the solvent was removed, the mixture was washed with water, and freeze-dried. The crude product was recrystallized from dichloromethane:methanol=1:3 (V / V) to obtain compound 1b.

[0059] Characterization data: 1 H NMR (600 MHz, DMSO-d 6 )δ:8.02(d,2H,J=8.98,ArH),7.48(d,1H,J=8.78Hz,ArH),7.05(d,1H,J=2.01Hz,ArH),6.9 5(d,2H,J=8.98,ArH),6.88(1H,dd,J=8.78,2.01Hz,ArH),3.84-3.77(overlapped,11H,OCH 3 ,CH 2 ). 13 C NMR (150 MHz, DMSO-d 6)δ:154.76,151.45,149.39,126.01,111.99,56.91,51.79,41.09.R-MS(ESI)calcd forC 18 H 20 Cl 2 N 3 O[M+H] + 364.0983, found 364.0986.

[0060] Example 3

[0061] The structural formula of compound 1c is as follows:

[0062]

[0063] Preparation of compound 1c:

[0064] 4-Nitro-o-phenylenediamine (1 mmol) and 4-[bis(β-chloroethyl)amino]benzaldehyde (1 mmol) were added to DMF (20 mL), and propionic acid (20 μL) was added and heated at 120°C for 8 hours. Then the solvent was removed, washed with water, freeze-dried, and the crude product was recrystallized from dichloromethane:methanol=1:3 (V / V) to obtain compound 1c.

[0065] Characterization data: 1 H NMR (600 MHz, DMSO-d 6 )δ:13.32(s,1H,ArH),8.34(s,1H,ArH),8.07-8.01(overlapped,3H,ArH),7.65(d,1H,J=8.85Hz,ArH),6.93(d,2H,J=9.00Hz,ArH),3.84-3.73(m,8H,CH 2 ). 13 C NMR (150 MHz, DMSO-d 6 )δ:148.67,128.62,117.60,116.90,111.95,51.80,41.04.R-MS(ESI)calcd for C 17 H 17 Cl 2 N 4 O 2 [M+H] + 379.0729, found 379.0730.

[0066] Example 4

[0067] The structural formula of compound 1d is as follows:

[0068]

[0069] Preparation of compound 1d:

[0070] 4-Fluoro-o-phenylenediamine (1 mmol) and 4-[bis(β-chloroethyl)amino]benzaldehyde (1 mmol) were added to DMF (20 mL), propionic acid (20 μL) was added, and the mixture was heated at 120°C for 8 hours. Then the solvent was removed, the mixture was washed with water, and freeze-dried. The crude product was recrystallized from dichloromethane:methanol=1:3 (V / V) to obtain compound 1d.

[0071] Characterization data: 1 H NMR (600 MHz, DMSO-d 6 )δ:12.70(d,1H,J=7.41,NH),7.98-7.95(m,2H,ArH),7.55-7.39(m,1H,ArH),7.27( m,1H,ArH),6.99-6.92(m,1H,ArH),6.88(d,2H,J=8.96Hz,ArH),3.82-3.74(m,8H,CH 2 ). 13 C NMR (150 MHz, DMSO-d 6 )δ:153.74,147.91,136.93,131.66,128.00,111.83,111.14,103.64,97.09,51.86,41.07.R-MS(ESI)calcd forC 17 H 17 Cl 2 FN 3 [M+H] + 352.0784, found 352.0781.

[0072] Example 5

[0073] The structural formula of compound 1e is as follows:

[0074]

[0075] Preparation of compound 1e:

[0076] 4-Chloro-o-phenylenediamine (1 mmol) and 4-[bis(β-chloroethyl)amino]benzaldehyde (1 mmol) were added to DMF (20 mL), and propionic acid (20 μL) was added and heated at 120°C for 8 hours. Then the solvent was removed, washed with water, freeze-dried, and the crude product was recrystallized from dichloromethane:methanol=1:3 (V / V) to obtain compound 1e.

[0077] Characterization data: 1 H NMR (600 MHz, DMSO-d 6 )δ:12.62(s,1H,NH),8.00(d,2H,J=8.98Hz,ArH),7.55(s,1H,ArH),7.51(d,1H,J=8.66Hz, ArH),7.15(dd,1H,J=8.66,2.02Hz,ArH),6.92(d,2H,J=8.98Hz,ArH),3.84-3.77(m,8H,CH 2 ). 13 C NMR (150 MHz, DMSO-d 6 )δ:153.27,148.04,128.14,125.80,121.67,125.80,121.67,117.64,111.85,51.84,41.07.R-MS(ESI)calcd for C 17 H 17 Cl 3 N 3 [M+H] + 368.0488, found 368.0485.

[0078] Example 6

[0079] The structural formula of compound 1f is as follows:

[0080]

[0081] Preparation of compound 1f:

[0082] 4-Bromo-o-phenylenediamine (1 mmol) and 4-[bis(β-chloroethyl)amino]benzaldehyde (1 mmol) were added to DMF (20 mL), propionic acid (20 μL) was added, and the mixture was heated at 120°C for 8 hours. Then the solvent was removed, the mixture was washed with water, and freeze-dried. The crude product was recrystallized from dichloromethane:methanol=1:3 (V / V) to obtain compound 1f.

[0083] Characterization data: 1 H NMR (600 MHz, DMSO-d 6 )δ:7.93(d,2H,J=9.01Hz,ArH),7.62(s,1H,ArH),7.40(d,1H,J=8.60Hz,ArH),7. 20(dd,1H,J=8.60,1.50Hz,ArH),6.85(d,2H,J=9.01Hz,ArH),3.78-3.70(m,8H,CH 2 ). 13C NMR (150 MHz, DMSO-d 6 )δ:153.25,148.02,128.17,124.23,117.83,113.56,111.88,51.89,41.12.R-MS(ESI)calcd for C 17 H 17 Cl 3 N 3 [M+H] + 368.0488, found 368.0485.

[0084] Example 7

[0085] The structural formula of compound 1g is as follows:

[0086]

[0087] Preparation of compound 1g:

[0088] 3,4-Diaminobenzonitrile (1 mmol) and 4-[bis(β-chloroethyl)amino]benzaldehyde (1 mmol) were added to DMF (20 mL), propionic acid (20 μL) was added, and the mixture was heated at 120°C for 8 hours. Then the solvent was removed, the mixture was washed with water, and freeze-dried. The crude product was recrystallized from dichloromethane:methanol=1:3 (V / V) to obtain 1 g of compound.

[0089] Characterization data: 1 H NMR (600 MHz, DMSO-d 6 )δ:8.07-8.04(overlapped,3H,ArH),7.69(d,1H,J=8.38Hz,ArH),7.58(dd,1H,J=8.38,1.50Hz,ArH),6.95(d,2H,J=9.03Hz,ArH),3.86-3.77(m,8H,CH 2 ). 13 C NMR (150 MHz, DMSO-d 6 )δ:154.61,149.48,130.03,127.51,120.09,114.79,110.79,102.08,49.97,41.11.R-MS(ESI)calcd for C 18 H 17 Cl 2 N 4 [M+H] + 359.0830, found 359.0828.

[0090] Example 8

[0091] The structural formula of compound 1h is as follows:

[0092]

[0093] Preparation of compound 1h:

[0094] 3,4-Diaminobenzoic acid (1 mmol) and 4-[bis(β-chloroethyl)amino]benzaldehyde (1 mmol) were added to DMF (20 mL), propionic acid (20 μL) was added, and the mixture was heated at 120°C for 8 hours. Then the solvent was removed, the mixture was washed with water, and freeze-dried. The crude product was recrystallized from dichloromethane:methanol=1:3 (V / V) to obtain compound 1h.

[0095] Characterization data: 1 H NMR (600 MHz, DMSO-d 6 )δ:12.73(s,1H,NH),8.01(d,2H,J=8.98Hz,ArH),7.98(d,1H,J=8.18Hz,ArH),7.39(s,1H,ArH),6.89(d,2H,J=8.98Hz,ArH),3.85-3.76(m,8H,CH 2 ). 13 C NMR (150 MHz, DMSO-d 6 )δ:147.55,127.95,118.76,111.78,51.92,41.12.R-MS(ESI)calcd for C 18 H 18 Cl 2 N 3 O 2 [M+H] + 378.0776, found 378.0779.

[0096] Effect example

[0097] In vitro antiproliferative activity:

[0098] When the tumor cells (A549 and Hela) were in the logarithmic growth phase, approximately 2×10 3 After 24 hours of cell attachment, add 100 μM of different concentrations of drugs diluted in medium containing 10% FBS to each well and put it into the 37°C incubator again. After 72 hours of cell culture, discard the medium in the 96-well plate, add 100 μL of CCK8 reagent to each well, and continue to incubate in the incubator for 2 hours. Read the OD of each well with an enzyme-labeled instrument. 450 Numerical values ​​were used to calculate the changes in cell activity after treatment with different drug concentrations.

[0099] The results of the antiproliferative activities of the products 1a to 1h prepared in Examples 1 to 8 on A549 and Hela cells are shown in Figures 1 to 8 As can be seen from the figure, with the increase of compound concentration, the ability to inhibit the proliferation of A549 and Hela cells continued to increase, and compounds 1a~1h all showed good anti-tumor activity. Among them, in comparison, the anti-proliferation activity of compounds 1a~1h on Hela cells was slightly stronger than that on A549 cells. The anti-tumor proliferation activity of different compounds was also slightly different. The most active one was compound 1g, with a half inhibitory concentration (IC 50 ) was 21.3μM, and the half-inhibitory concentration for Hela cells was 15.8μM. The activity of 1d was second, and its activity was close to 1g, with the half-inhibitory concentrations for A549 cells and Hela cells being 23.3μM and 16.1μM, respectively. The next closest activities were 1h, 1b, and 1c. The activity of 1a was relatively weak, but it still showed obvious antiproliferative activity against tumor cells, with the half-inhibitory concentrations for A549 cells and Hela cells being 47.2μM and 36.7μM, respectively.

[0100] From the above structure-activity relationship, it can be seen that when the 5th position on the imidazole ring is substituted with a halogen, it has good activity, among which the activity of fluorine is slightly greater than that of chlorine and bromine. In addition, the activity of fluorine and cyanide is similar. When there is no substituent on the imidazole ring, the activity is relatively weak. The above results show that the synthesized 4-(1H-benzo[d]imidazol-2-yl)-N, N-bis(2-chloroethyl)aniline derivatives have obvious anti-tumor activity.

[0101] Obviously, the above embodiments of the present invention are merely examples for clearly illustrating the present invention, and are not intended to limit the implementation methods of the present invention. For ordinary technical users in the relevant field, other different forms of changes or modifications can be made on the basis of the above description. It is not necessary and impossible to list all the implementation methods here. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the claims of the present invention.

Claims

1. A 4-(1H-benzo[d]imidazol-2-yl)-N,N-bis(2-chloroethyl)aniline derivative, characterized in that: Its structural formula is shown in Formula I: Wherein, the R substituent is selected from any one of hydrogen, halogen, carboxyl, cyano, nitro and alkoxy.

2. The method for preparing the 4-(1H-benzo[d]imidazol-2-yl)-N,N-bis(2-chloroethyl)aniline derivative according to claim 1, characterized in that: The following reactions are included: The method comprises the following steps: adding 4-substituted o-phenylenediamine and 4-[bis(β-chloroethyl)amino]benzaldehyde into a solvent, heating for reaction, and then recrystallizing the reaction product to obtain the 4-(1H-benzo[d]imidazol-2-yl)-N,N-bis(2-chloroethyl)aniline derivative.

3. The preparation method according to claim 2, characterized in that: The molar ratio of the 4-substituted o-phenylenediamine to 4-[bis(β-chloroethyl)amino]benzaldehyde is 1:

1.

4. The preparation method according to claim 2, characterized in that: The solvent is selected from at least one of ethanol, propanol, N,N-dimethylformamide and N,N-dimethylacetamide.

5. The preparation method according to claim 2, characterized in that: The conditions of the heating reaction are: the reaction is carried out under the catalysis of a catalyst, the reaction temperature is 110° C. to 150° C., and the reaction time is 4 to 10 hours.

6. The preparation method according to claim 5, characterized in that: The catalyst is selected from at least one of acetic acid, propionic acid and p-toluenesulfonic acid.

7. The preparation method according to claim 2, characterized in that: The solvent for the recrystallization is: dichloromethane:methanol=1:3 (V / V).

8. Use of the 4-(1H-benzo[d]imidazol-2-yl)-N,N-bis(2-chloroethyl)aniline derivative as claimed in claim 1 in the preparation of anti-tumor drugs, characterized in that: The tumor is cervical cancer or non-small cell lung cancer.

9. An anti-tumor drug, characterized in that: It includes the 4-(1H-benzo[d]imidazol-2-yl)-N,N-bis(2-chloroethyl)aniline derivative described in claim 1.

10. The anti-tumor drug according to claim 9, characterized in that: Pharmaceutically acceptable excipients are also included.

Citation Information

Patent Citations

  • Treatment for cancer

    CN101111248A

  • Benzimidazole ring-containing propiolamide derivative, preparation method, pharmaceutical composition and application thereof

    CN105085406A

  • Benzoimidazole derivatives as anticancer agents

    CN110234640A

  • Chlormethine-containing imidazole heterocyclic derivative, preparation method and application thereof

    CN113387892A

  • Anthracene and nitrogen mustard substituted alpha, beta unsaturated ketone compound as well as preparation and application thereof

    CN114591189A